Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cumulative genetic risk for asthma contributes to disease severity in children with asthma.

The journal of allergy and clinical immunology. Global·2026
Same author

Epigenetic gestational age acceleration in cord blood is associated with activated inflammatory gene pathways and childhood asthma.

The Journal of allergy and clinical immunology·2026
Same author

Upper airway microbiome interacts with GSDMB and ORMDL3 asthma risk SNPs to influence early-life wheeze risk.

The Journal of allergy and clinical immunology·2026
Same author

The Michigan Sibling Immunity Birth Study (M-SIBS): Study design protocol for a unique food allergy birth cohort.

The journal of allergy and clinical immunology. Global·2026
Same author

The association of newborn metabolites with early-life wheezing and asthma among US children in the ECHO Program.

Communications medicine·2026
Same author

Multicohort analysis unveils axon guidance pathways linking small for gestational age to spirometric restriction.

Nature communications·2026

Related Experiment Video

Updated: Jan 3, 2026

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K

Exacerbation-Prone Asthma.

Loren C Denlinger1, Peter Heymann2, Rene Lutter3

  • 1Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wis.

The Journal of Allergy and Clinical Immunology. in Practice
|November 26, 2019
PubMed
Summary
This summary is machine-generated.

Asthma exacerbations incur high costs, driven by environmental factors and patient-specific risks. New biologic therapies target inflammation, but challenges remain for widespread use and treating acute attacks.

Keywords:
CorticosteroidsExacerbation-prone asthmaPrecision interventionsType 2 inflammation

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.2K

Related Experiment Videos

Last Updated: Jan 3, 2026

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.2K

Area of Science:

  • Pulmonary Medicine
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma exacerbations lead to significant patient morbidity and healthcare costs.
  • Environmental exposures (pollutants, pathogens) and patient factors (phenotype, age, allergic sensitization) trigger exacerbations.
  • Airway inflammation, including eosinophilic, type 2, and neutrophilic types, is a key risk factor.

Purpose of the Study:

  • To review current understanding of asthma exacerbation triggers and risk factors.
  • To discuss novel biologic therapies targeting type 2 inflammation for exacerbation prevention.
  • To highlight challenges in precision medicine and treatment of acute asthma attacks.

Main Methods:

  • Literature review of asthma exacerbation mechanisms and treatments.
  • Analysis of risk factors including environmental exposures, genetics, and biomarkers.
  • Evaluation of biologic therapies targeting specific inflammatory pathways.

Main Results:

  • Allergic sensitization in children and airway inflammation are significant risk factors for exacerbations.
  • Monoclonal antibody (mAb) biologics targeting type 2 pathways show promise for exacerbation prevention.
  • Evidence gaps exist for precision interventions, especially in young children, and for acute exacerbation treatments.

Conclusions:

  • Understanding inflammatory pathways is crucial for developing new asthma exacerbation prevention strategies.
  • Biologics offer new hope for high-risk patients, but cost and applicability require further study.
  • Developing effective treatments for acute asthma exacerbations remains a critical unmet need.